Clinical Study on Autologous Stromal Vascular Fraction(SVF) Treatment for Refractory Benign Airway Stenosis and Respiratory Tract Fistula
Clinical Study on Autologous Stromal Vascular Fraction(SVF) Treatment for Benign Airway Stenosis and Respiratory Tract Fistula
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Xinyu Song, MD
- Phone Number: 86-020-83062885
- Email: songxy_2021@163.com
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510120
- Recruiting
- Guangzhou Institute of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University
-
Contact:
- Xinyu Song, MD
- Phone Number: 8620-83062896
- Email: songxy_2021@163.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects aged between 18 to 75
- Subjects diagnosed with benign airway stenosis, tracheoesophageal fistula(the sizes of the fistulas less than 2cm), and bronchopleural fistula
- Subjects willing to accept SVF treatment
- Subjects tolerant to the bronchoscope
- Subjects signed informed consent
Exclusion Criteria:
- Subjects with the following pulmonary diseases: asthma, active pulmonary tuberculosis, pulmonary embolism, pneumothorax, pulmonary hypertension, etc;
- Subjects with incomplete remission of malignant tumors or with incurable malignant tumors;
- Subjects with uncontrolled systemic infection;
- Subjects requiring anti-clotting drugs;
- Subjects with myocardial infarction, unstable angina, liver cirrhosis, acute glomerulonephritis, etc;
- Subjects with syphilis, HIV, HBV, HCV antibody positive;
- Subjects with Coagulation disorders such as hemophilia, giant platelet syndrome, thromboasthenia, etc;
- Subjects with severe renal damage, serum creatinine is more than 1.5 times the upper limit of the normal value;
- Subjects with liver disease or liver damage: ALT, AST, total bilirubin > 2 times the upper limit of the normal value;
- Subjects with a history of psychosis or suicide or epilepsy or other central nervous system diseases;
- Subjects with severe arrhythmias(e.g. ventricular tachycardia, frequent supraventricular tachycardia, atrial fibrillation, atrial flutter, etc.) or degree II above abnormal conduction;
- Subjects allergic to thrombin;
- Subjects accepted by any other clinical study within the first three months of the study;
- Subjects with poor compliance;
- Any other conditions might increase the risk of the patient or interfere with the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Control group
Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
|
Conventional treatment for benign airway stenosis Including, but is not limited to laser, high-frequency electric knife, argon plasma coagulation (APC), cryotherapy, balloon dilation, and metal stent placement
|
|
Experimental: SVF group
SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula.
|
SVF treatment following the conventional treatment for benign airway stenosis and respiratory tract fistula
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cure rate for benign airway stenosis
Time Frame: within 3 months after administration
|
The proportion of patients who is no need for endotracheal intervention and with stable clinical symptoms after SVF treatment
|
within 3 months after administration
|
|
Cure rate for respiratory tract fistula
Time Frame: within 3 months after administration
|
The proportion of patients who have complete closure of fistula, no need for endotracheal intervention and with stable clinical symptoms after SVF treatment
|
within 3 months after administration
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Clinical complete remission time
Time Frame: within 3 months after administration
|
The interval time of the first intratracheal interventional therapy needed again after SVF treatment
|
within 3 months after administration
|
|
Times of unplanned treatment
Time Frame: within 3 months after administration
|
The number of times a patient needs to be reviewed and treated by bronchoscopy
|
within 3 months after administration
|
|
Incidence of complications associated with SVF treatment
Time Frame: within 3 months after administration
|
Wound healing, sputum retention, etc. during follow-up
|
within 3 months after administration
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 20220210
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.